B2DB — Who said what, where, and when

Michael Scholle

Chief Executive Officer, Tango Biosciences, Inc.

Michael Scholle is listed as Chief Executive Officer, Tango Biosciences, Inc.. Michael is scheduled to speak at SLAS 2027 International Conference & Exhibition on 2 February 2027.

Compiled from published conference agendas; not yet confirmed by Michael. Is this you? Claim this profile.

About

Michael Scholle serves as the new CEO of Tango Biosciences as of Jan 2025. He has previously served as Chief Operating Officer and co-founder of SAMDI Tech, prior to its acquisition by Charles River Labs in Jan 2022, where until recently he served as Operations Director and Site Head. He previously held positions form Director to Vice President at SAMDI Tech from 2011-2018. Prior to SAMDI Tech, Scholle held various scientific and management positions at Integrated Genomics Inc, Argonne National Laboratory, and Amunix Inc. At Amunix, he was a founding scientist and played a key role in the development of XTEN, a half-life enhancing technology. XTEN technology was taken public by Versartis with an IPO in 2013 and Amunix was acquired by Sanofi in 2022. Scholle has served on the Board of Directors at Amunix and Tango Biosciences prior to becoming its CEO. He has authored over 30 peer-reviewed articles published in scientific and business journals. Scholle has a master’s degree in biology f

Upcoming

SLAS 2027 International Conference & Exhibition 30 January 2027 – 3 February 2027